# A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Source: https://onco.cc/trials/nct07229599/  
OnCo record `nct07229599` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Furmonertinib and Carboplatin in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.

## Summary

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer is a phase 1/2 interventional study registered as NCT07229599 by Minghui Pharmaceutical (Hangzhou) Ltd, with 300 participants planned, started 2025-05-09 and due to reach its primary completion in 2029-05. Interventions recorded: MHB036C for Injection, MHB039A for Injection, Furmonertinib and Carboplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07229599
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate the Efficacy and Safety of MHB036C for Injection Combined With Other Anti-tumor Therapy in Patients With Advanced Lung Cancer
- Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT07229599: https://clinicaltrials.gov/study/NCT07229599

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Furmonertinib](https://onco.cc/drugs/furmonertinib/), [MHB036C](https://onco.cc/drugs/mhb036c/), [MHB039A](https://onco.cc/drugs/mhb039a/)

---
JSON: https://onco.cc/api/v1/entities/nct07229599.json